D054198DisordersC04.557.337.428.600C15.604.515.560.600C20.683.515.528.60040427930.373234Precursor Cell Lymphoblastic Leukemia-LymphomaFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonLeukemiaStem Cell TransplantationMD AndersonHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorPARTOWKEBRIAEIPARTOW KEBRIAEI8535KEBRIAEI, PARTOWProfessorELIAS JOSEPHJABBOURELIAS JOSEPH JABBOUR9124JABBOUR, ELIAS JOSEPHAssociate Professor74Professor14Associate Professor30.59960.00232977404research area of0.9943230.02161081136subject area forDepartment of PediatricsPediatrics-OncologyBaylor College of MedicineKARENRABINKAREN RABIN0.000000000000000.000000000000001020RABIN, KARENProfessorMICHAELSCHEURERMICHAEL SCHEURER0.000000000000000.000000000000001350SCHEURER, MICHAEL0000-0002-8379-6088Professortrue1ProfessorProfessortrue1ProfessorProfessorPediatric-Oncology EPI37646654Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki KHaematologicaMyeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 Jan 01; 109(1):293-297.Haematologica2024-01-01T00:00:002024Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies.37556734Wood BL, Devidas M, Summers RJ, Chen Z, Asselin B, Rabin KR, Zweidler-McKay PA, Winick NJ, Borowitz MJ, Carroll WL, Raetz EA, Loh ML, Hunger SP, Dunsmore KP, Teachey DT, Winter SSBloodPrognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.Blood2023-12-14T00:00:002023Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.37879077Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian HBloodPhase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421.Blood2024-02-01T00:00:002024Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.38207208Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian HBlood advancesA phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2024 Feb 27; 8(4):909-915.Blood Adv2024-02-27T00:00:002024A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.38317420Jabbour E, Zugmaier G, Agrawal V, Mart?nez-S?nchez P, Rif?n Roca JJ, Cassaday RD, B?ll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, D?az MT, Vucinic V, Gonz?lez-Campos J, Rambaldi A, Schwartz S, Berthon C, Hern?ndez-Rivas JM, Gordon PR, Br?ggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian HAmerican journal of hematologySingle agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 Apr; 99(4):586-595.Am J Hematol2024-02-05T00:00:002024Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.true1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor